Study Stopped
Intepirdine did't meet primary efficacy endpoints in lead-in study RVT-101-3001
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
1 other identifier
interventional
1,099
19 countries
169
Brief Summary
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2016
169 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 23, 2015
CompletedFirst Posted
Study publicly available on registry
October 27, 2015
CompletedStudy Start
First participant enrolled
April 26, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 12, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 12, 2018
CompletedResults Posted
Study results publicly available
April 17, 2020
CompletedApril 17, 2020
March 1, 2018
1.9 years
October 23, 2015
January 6, 2020
April 14, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Occurrence of Adverse Events (AEs) and or Reported Changes in Physical Examinations, Vital Signs Measurements, Electrocardiograms (ECGs), Routine Laboratory Assessments
The primary outcome measure is to study the safety of Intepridine (RVT-101) by determining the incidence of AEs, changes in physical examinations, vital signs measurements, ECGs and clinical laboratory assessments
Baseline to 12 months or Early Termination
Study Arms (1)
RVT-101 35 mg tablets
EXPERIMENTALonce daily, oral tablets
Interventions
Eligibility Criteria
You may qualify if:
- Completed last on-treatment visit of the lead-in study RVT-101-3001
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (169)
US112
Phoenix, Arizona, 85005, United States
US220
Tucson, Arizona, 85704, United States
US096
Rancho Mirage, California, 92270, United States
US195
Santa Ana, California, 92705, United States
US016
Simi Valley, California, 93065, United States
US106
Temecula, California, 92591, United States
US179
Hamden, Connecticut, 06518, United States
US171
Norwich, Connecticut, 06360, United States
US088
Atlantis, Florida, 33462, United States
US007
Brooksville, Florida, 34601, United States
US002
Hallandale, Florida, 33009, United States
US140
Hialeah, Florida, 33012, United States
US216
Miami, Florida, 33137, United States
US110
Miami, Florida, 33165, United States
US172
North Palm Beach, Florida, 33408, United States
US003
Orlando, Florida, 32806, United States
US256
Pensacola, Florida, 32502, United States
US037
Tampa, Florida, 33613, United States
US042
Tampa, Florida, 33613, United States
US004
The Villages, Florida, 32162, United States
US048
Atlanta, Georgia, 30331, United States
US046
Atlanta, Georgia, 30342, United States
US217
Columbus, Georgia, 31909, United States
US111
Baton Rouge, Louisiana, 70808, United States
US095
Shreveport, Louisiana, 71104, United States
US116
Newton, Massachusetts, 02459, United States
US174
Quincy, Massachusetts, 02169, United States
US144
Hattiesburg, Mississippi, 39401, United States
US094
Las Vegas, Nevada, 89113, United States
US135
Berlin, New Jersey, 08009, United States
US197
Lawrenceville, New Jersey, 08648, United States
US215
Mount Arlington, New Jersey, 07856, United States
US057
Paterson, New Jersey, 08759, United States
US209
Toms River, New Jersey, 08755, United States
US036
West Long Branch, New Jersey, 07764, United States
US001
Albany, New York, 12208, United States
US049
Brooklyn, New York, 11235, United States
US097
New Hyde Park, New York, 11040, United States
US044
New York, New York, 10022, United States
US150
Chapel Hill, North Carolina, 27599, United States
US185
Charlotte, North Carolina, 28270, United States
US008
Cincinnati, Ohio, 45227, United States
US113
Cleveland, Ohio, 44106, United States
US119
Shaker Heights, Ohio, 44122, United States
US134
Portland, Oregon, 97210, United States
US169
Media, Pennsylvania, 19063, United States
US162
Plains, Pennsylvania, 18075, United States
US148
Willow Grove, Pennsylvania, 19001, United States
US043
San Antonio, Texas, 78229, United States
US143
Orem, Utah, 84058, United States
US149
Charlottesville, Virginia, 22903, United States
US170
Spokane, Washington, 99202, United States
AR130
La Plata, Buenos Aires, A1902AJU, Argentina
AR101
Buenos Aires, B1828CKR, Argentina
AR060
Buenos Aires, C1199ABB, Argentina
AR084
Ciudad Autonoma de Buenos Aire, C1012AAR, Argentina
AR027
Ciudad Autonoma de Buenos Aire, C1058AAJ, Argentina
AR012
Ciudad Autonoma de Buenos Aire, C1111AAL, Argentina
AR160
Ciudad Autonoma de Buenos Aire, C1117ABH, Argentina
AR028
Ciudad Autonoma de Buenos Aire, C1406BOA, Argentina
AR035
Ciudad Autonoma de Buenos Aire, C1428AQK, Argentina
AR040
Ciudad Autónoma de Buenos Aire, C1405BCK, Argentina
AR081
Ciudad Autónoma de Buenos Aire, C1425AHQ, Argentina
AR051
Córdoba, X5000DCE, Argentina
AR137
Córdoba, X5000FJF, Argentina
AR126
Córdoba, X5004AOA, Argentina
AR210
Mendoza, M5501ACP, Argentina
AR219
Mendoza, M5502AHV, Argentina
AR059
Santiago del Estero, G4200DND, Argentina
AU227
Caulfield, VIC 3162, Australia
AU032
Heidelberg West, VIC 3081, Australia
AU011
Hornsby, NSW 2077, Australia
AU138
West Perth, WA 6005, Australia
BU125
Rousse, 7003, Bulgaria
BU131
Sofia, 1431, Bulgaria
BU073
Varna, 9000, Bulgaria
CA054
Kelowna, British Columbia, V1Y 1Z9, Canada
CA188
Kelowna, British Columbia, V1Y 4N7, Canada
CA186
Penticton, British Columbia, V2A 5C8, Canada
CA141
West Vancouver, British Columbia, V7T 2Z3, Canada
CA147
Newmarket, Ontario, L3Y 5G8, Canada
CA196
North York, Ontario, M3B 2S7, Canada
CA236
Gatineau, Quebec, J8T 8JI, Canada
CH212
Antofagasta, Antofagasta, 1270244, Chile
CH061
Santiago, Santiago Metropolitan, 7510186, Chile
CH075
Santiago, Santiago Metropolitan, 7520338, Chile
CH076
Santiago, Santiago Metropolitan, 7560356, Chile
CR069
Zagreb, 10000, Croatia
CR122
Zagreb, 10000, Croatia
CR070
Zagreb, 10090, Croatia
CZE128
Prague, 100 00, Czechia
CZE207
Prague, 100 00, Czechia
CZE132
Prague, 12000, Czechia
CZE129
Prague, 160 00, Czechia
CZE161
Rychnov nad Kněžnou, 516 01, Czechia
FR231
Lille, 59037, France
FR182
Marseille, 13385, France
FR221
Paris, 75013, France
FR202
Villeurbanne, 69 100, France
GE206
Bad Homburg, 61348, Germany
GE091
Berlin, 10117, Germany
GE071
Berlin, 12203, Germany
GE139
Berlin, 13125, Germany
GE230
Cologne, 50937, Germany
GE252
Ellwangen, 73479, Germany
GE180
Leipzig, 04107, Germany
GE228
Mannheim, 68165, Germany
GE017
München, 81675, Germany
GE157
Nuremberg, 90402, Germany
GE098
Ulm, 89081, Germany
GE251
Westerstede, 26655, Germany
IT053
Brescia, 25125, Italy
IT124
Cefalù, 90015, Italy
IT030
Pavia, 27100, Italy
IT103
Perugia, 06156, Italy
IT072
Roma, 00168, Italy
IT029
Roma, 00189, Italy
IT183
Rome, 00179, Italy
IT175
Rome, 00185, Italy
IT085
Torino, 10 126, Italy
PO013
Bialystok, 15-756, Poland
PO024
Bydgoszcz, 85-080, Poland
PO010
Bydgoszcz, 85-796, Poland
PO107
Katowice, 40-123, Poland
PO092
Katowice, 40-749, Poland
PO009
Poznan, 61-853, Poland
PO014
Szczecin, 70-111, Poland
PO074
Warsaw, 01-697, Poland
SE164
Belgrade, 11 000, Serbia
SE193
Belgrade, 11 000, Serbia
SE090
Belgrade, 11000, Serbia
SE155
Kragujevac, 34 000, Serbia
SE031
Novi Kneževac, 23330, Serbia
SE165
Vršac, 26300, Serbia
SI052
Singapore, 119074, Singapore
SI026
Singapore, 308433, Singapore
SL056
Banská Bystrica, 974 04, Slovakia
SL200
Dubnica nad Váhom, 018 41, Slovakia
SL078
Krompachy, 040 01, Slovakia
SL078
Krompachy, 05342, Slovakia
SL077
Svidník, 08901, Slovakia
SK066
Busan, 49201, South Korea
SK067
Seoul, 06351, South Korea
SK190
Seoul, 07061, South Korea
SP249
Alicante, 03690, Spain
SP176
Barcelona, 08003, Spain
SP022
Barcelona, 08028, Spain
SP021
Barcelona, 08035, Spain
SP250
Barcelona, 08036, Spain
SP184
Barcelona, 08195, Spain
SP222
Getxo, 48993, Spain
SP194
San Sebastián, 20014, Spain
TA121
Taoyuan District, 333, Taiwan
UK063
Bath, BA1 3NG, United Kingdom
UK038
Blackpool, FY2 0JH, United Kingdom
UK233
Cambridge, CB21 5EF, United Kingdom
UK033
Carnoch, WS11 0BN, United Kingdom
UK211
Epping, CM16 6TN, United Kingdom
UK234
Guildford, GU2 7YD, United Kingdom
UK055
Leeds, LS10 1DU, United Kingdom
UK039
London, W1G 9RU, United Kingdom
UK034
Manchester, M13 9NQ, United Kingdom
UK087
Oxford, OX3 9DU, United Kingdom
UK235
Plymouth, PL5 8BT, United Kingdom
UK100
Sheffield, S5 7JT, United Kingdom
UK064
Southampton, SO16 6YD, United Kingdom
UK152
Southampton, SO30 3JB, United Kingdom
UK153
Swindon, SN3 6BW, United Kingdom
UK154
Warrington, WA22 8WA, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Yi Mo, PhD
- Organization
- Axovant Gene Therapies
Study Officials
- STUDY DIRECTOR
Ilise Lombardo, MD
Axovant Sciences, Inc., Vice President, Clinical Research
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 23, 2015
First Posted
October 27, 2015
Study Start
April 26, 2016
Primary Completion
March 12, 2018
Study Completion
March 12, 2018
Last Updated
April 17, 2020
Results First Posted
April 17, 2020
Record last verified: 2018-03
Data Sharing
- IPD Sharing
- Will not share